Active Biotech AB Year-end report January - December 2014

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Active Biotech AB Year-end report January - December 2014

Laquinimod · The pivotal CONCERTO clinical study is continuing according to plan and results are expected in 2016. · In May 2014, EMA's Committee for Medicinal Products for Human Use (CHMP) announced that the risks observed in animal studies did not prevent registration for treatment in humans. CHMP confirmed its January 2014 risk-benefit opinion, that is, to at this stage recommend against approval of laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) in the European Union (EU). · In September 2014, new follow-up data was presented from the extension studies following ALLEGRO and BRAVO. No new risks were identified and the rates of adverse events (AEs) were lower in the open-label extensions than in the core studies. Less than 3 percent of patients discontinued treatment due to AEs during these extensions. The safety profile of laquinimod when used in a longer- term setting was hence confirmed. · In November 2014, it was announced that Teva will initiate a Phase II trial with laquinimod for the treatment of primary progressive multiple sclerosis (PPMS). The first patient had been screened in a Phase II trial in Huntington's disease. Tasquinimod · The Phase III study 10TASQ10 is proceeding as planned; the final analysis of progression-free survival (PFS) and overall survival (OS) is expected during the first half of 2015. · In February 2014, Ipsen launched a randomized, double-blind, placebo- controlled Phase III study of tasquinimod in chemo-naive castrate-resistant prostate cancer (CRPC) patients in Asia. · In September 2014, Ipsen announced the preliminary results of the clinical Phase II proof-of-concept study in four cancer indications. The study for the treatment of hepatocellular carcinoma is continuing with results expected in 2015. The results do not support the further development of tasquinimod for the treatment of patients with advanced ovarian, renal cell or gastric carcinomas. The primary endpoint of the study was progression-free survival (PFS) at a predefined time for each cohort. ANYARA · During the year, it was decided to only conduct commercial activities in relation to the project. Out-licensing activities are ongoing. Paquinimod (57-57) · During the year, it was decided to only conduct commercial activities in relation to the project. Out-licensing activities are ongoing. ISI · The project is proceeding according to plan. The selection of the first candidate drug is planned to take place during 2015. Financial information · A rights issue totaling approximately SEK 225 M was completed in December 2014 and was oversubscribed by 24 percent. Financial summary MSEK Oct. - Dec.   Jan. - Dec.   2014 2013   2014 2013 --------------------------------------------------------------- Net sales 2.9 4.0   10.4 116.0 Operating loss -55.6 -80.4   -228.5 -209.0 Loss for the period -57.0 -82.1   -231.5 -212.1 Loss per share (SEK) -0.73 -1.07   -3.02 -2.81 Cash and cash equivalents (Dec 31)       328.5 376.2 For further information, please contact: Tomas Leanderson, President and CEO Active Biotech AB Tel: +46 (0)46 19 20 95 (Corp. Reg. No. 556223-9227)   Box 724, SE-220 07 Lund, Sweden Hans Kolam, CFO Tel: +46 (0)46 19 20 00 Tel: +46 (0)46 19 20 44 Fax: +46 (0)46 19 11 00 The report is also available at www.activebiotech.com [HUG#1893344]

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 538

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
Layne's Chicken Fingers Expands with Brownsville Opening

Updated Category News Views 395

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

Continue Reading
YSTUDIO's Pens: A Nod to the Power of Writing

Updated Category News Views 557

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West

Updated Category News Views 265

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 14

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 432

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 43

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 0

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 50

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 305

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading

Top 5 Most Recently Viewed Articles

ASE Advises Car Checkups Amid Rising Gas Prices

Updated Category News Views 18

Cars, Gas, and Good Old-Fashioned Maintenance If you've been hitting the road lately, you might've noticed gas prices biting a bit deeper into your wallet. The National Institute for Automotive Service Excellence (ASE) has something to say about that. They're dropping some knowledge on how an ASE Certified automotive service professional can help your vehicle run more...

Continue Reading
Impact of US Surgeon General's Cancer Warning on Spirits Stocks

Updated Category News Views 195

Market Reactions to Health Alerts in Alcohol Industry Recent comments from health officials can significantly sway market sentiments, especially in industries tied closely to public health. After the U.S. Surgeon General raised concerns about the impact of alcoholic beverages on health, European spirits manufacturers and brewers experienced a noticeable drop in their...

Continue Reading
Exploring Enterprise Products Partners: A Comprehensive Guide

Updated Category News Views 221

Enterprise Products Partners made waves as a midstream master limited partnership (MLP), catching the eye of specific investor types. This ain’t your usual stock; it’s got some quirks that make it unique, particularly its impressive 7.1% distribution yield, which can sound tempting but also rings alarm bells for those hunting growth. Distribution Yield: A Double-Edged...

Continue Reading
Gentoo Media Shareholders Decide on Euronext Delisting Move

Updated Category News Views 201

Gentoo Media's Special Meeting of Shareholders Overview A Special Meeting of Shareholders in Gentoo Media Inc. was conducted recently, attracting a considerable presence of shareholders. Those attending either in person or through proxy accounted for a noteworthy 51.18% of the shares with voting rights. Key Resolutions Made The primary resolution passed during this...

Continue Reading
Municipality Finance Successfully Issues USD 25 Million Tranche

Updated Category News Views 168

Municipality Finance Successfully Issues USD 25 Million Tranche Municipality Finance Plc has recently made headlines with the issuance of a new USD 25 million tranche under its Medium Term Note (MTN) program. This strategic move continues to bolster the company’s existing benchmark, which was initially introduced earlier this year. As of now, the cumulative nominal...

Continue Reading